MEREO BIOPHARMA GROUP PLC's ticker is MREO and the CUSIP is 589492107. A total of 62 filers reported holding MEREO BIOPHARMA GROUP PLC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2023 | $7,589 | -5.7% | 10,735 | 0.0% | 0.00% | – |
Q4 2022 | $8,051 | -10.5% | 10,735 | 0.0% | 0.00% | – |
Q3 2022 | $9,000 | -25.0% | 10,735 | 0.0% | 0.00% | – |
Q2 2022 | $12,000 | 0.0% | 10,735 | 0.0% | 0.00% | – |
Q1 2022 | $12,000 | -29.4% | 10,735 | 0.0% | 0.00% | -100.0% |
Q4 2021 | $17,000 | -34.6% | 10,735 | 0.0% | 0.00% | 0.0% |
Q3 2021 | $26,000 | -23.5% | 10,735 | 0.0% | 0.00% | 0.0% |
Q2 2021 | $34,000 | -5.6% | 10,735 | 0.0% | 0.00% | 0.0% |
Q1 2021 | $36,000 | -32.1% | 10,735 | -27.1% | 0.00% | -50.0% |
Q4 2020 | $53,000 | -63.2% | 14,735 | -73.1% | 0.00% | -71.4% |
Q3 2020 | $144,000 | -14.3% | 54,773 | 0.0% | 0.01% | -30.0% |
Q2 2020 | $168,000 | +115.4% | 54,773 | -26.7% | 0.01% | +66.7% |
Q1 2020 | $78,000 | -54.4% | 74,773 | +43.2% | 0.01% | -33.3% |
Q4 2019 | $171,000 | -26.6% | 52,199 | -33.3% | 0.01% | -40.0% |
Q3 2019 | $233,000 | +19.5% | 78,207 | +1.4% | 0.02% | +36.4% |
Q2 2019 | $195,000 | – | 77,152 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
COMMODORE CAPITAL LP | 2,048,757 | $6,904,000 | 2.75% |
Asymmetry Capital Management, L.P. | 1,063,264 | $3,583,000 | 1.85% |
Endurant Capital Management LP | 1,339,835 | $4,515,000 | 1.18% |
Altium Capital Management LP | 1,250,000 | $4,213,000 | 1.17% |
Affinity Asset Advisors, LLC | 900,000 | $3,033,000 | 1.03% |
DAFNA Capital Management LLC | 1,249,648 | $4,211,000 | 1.00% |
Boxer Capital, LLC | 6,226,673 | $20,984,000 | 0.71% |
Delphi Management Partners VIII, L.L.C. | 256,734 | $865,000 | 0.60% |
Rubric Capital Management LP | 2,914,861 | $9,823,000 | 0.57% |
Orbimed Advisors | 17,264,763 | $58,183,000 | 0.54% |